These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study. Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M; Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440 [TBL] [Abstract][Full Text] [Related]
4. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine. Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F; Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH; Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367 [TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G; Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569 [TBL] [Abstract][Full Text] [Related]
8. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. Pietruck F; Abbud-Filho M; Vathsala A; Massari PU; Po-Huang L; Nashan B Transplant Proc; 2007; 39(1):103-8. PubMed ID: 17275484 [TBL] [Abstract][Full Text] [Related]
9. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil. Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848 [TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis. Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293 [TBL] [Abstract][Full Text] [Related]
11. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074 [TBL] [Abstract][Full Text] [Related]
12. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N; J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114 [TBL] [Abstract][Full Text] [Related]
13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study. Nashan B; Ivens K; Suwelack B; Arns W; Abbud Filho M; ; Transplant Proc; 2004 Mar; 36(2 Suppl):521S-523S. PubMed ID: 15041400 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. Budde K; Knoll G; Curtis J; Kahana L; Pohanka E; Seifu Y; Neumayer HH Transplant Proc; 2005 Mar; 37(2):912-5. PubMed ID: 15848573 [TBL] [Abstract][Full Text] [Related]